Abhishek Kumar: New Horizons in Hemophilia B Treatment and Prevention
Abhishek Kumar, Lead Analyst at DelveInsight Business Research LLP, shared a post on LinkedIn:
“Hemophilia B: Genetics, Clotting Challenges, and Modern Treatment Advances
Hemophilia B is a rare inherited bleeding disorder caused by factor IX deficiency due to F9 gene mutations.
It follows an X linked recessive pattern, affecting mostly males while females are carriers.
Reduced factor IX disrupts the intrinsic coagulation pathway, leading to unstable clots and prolonged bleeding after injury.
Severity depends on factor levels.
Management focuses on replacing factor IX through recombinant or plasma derived concentrates, used on demand or prophylactically.
Newer options like extended half life therapies and gene therapy aim to improve long term control and quality of life.
Early diagnosis and care are essential for preventing complications.
Recent Developments in Hemophilia B Clinical Research
In March 2025, Sanofi announced that the U.S. Food and Drug Administration (FDA) approved Qfitlia, the first antithrombin-lowering (AT) therapy for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients (aged 12 or older) with Hemophilia A or B, with or without factor VIII or IX inhibitors.
The approval was based on data from the ATLAS phase 3 studies, which demonstrated clinically meaningful bleed protection as measured by annualized bleeding rates (ABR) across Hemophilia A and B patients, regardless of inhibitor status.
Key Hemophilia B Companies shaping the competitive landscape include: BIOCAD, Gyre Therapeutics, Be Biopharma, Regeneron Pharmaceuticals, Inc., Intellia Therapeutics, Inc., Suzhou Alphamab Co., Ltd., Equilibra Bioscience, UBI Pharma Inc., Staidson (Beijing) Biopharmaceuticals Co., Ltd, and others.
Explore in-depth insights and future market projections today.”
Stay updated with Hemostasis Today.
-
Aug 11, 2026, 04:10Haroun Gajraj: CLaCS vs Sclerotherapy – What Does the Evidence Show
-
Aug 11, 2026, 02:54Tareq Abadl: The Ultimate Guide to Clinically Significant Antibodies
-
Aug 10, 2026, 17:35Chokri Ben Lamine: Balancing Holistic Care and Precision in Hematology
-
Aug 10, 2026, 17:14Anna Stanizzi: Patient Blood Management as a New Model of Personalized Care
-
Aug 10, 2026, 17:12Odong Christopher: New Research on Ischemic Stroke Prediction in Uganda
-
Aug 10, 2026, 16:58Jeff Szer AM: Advancing the Management of Paroxysmal Nocturnal Hemoglobinuria
-
Aug 10, 2026, 16:51Suebsarn Ruksakulpiwat։ A New Milestone in the Development of the Stroke Risk Screening Scales
-
Aug 10, 2026, 16:09Preetie Shetty Akkunje: Making Stroke Rehabilitation Accessible in Low-Resource Settings
-
Aug 10, 2026, 15:50The Next Antithrombotic Frontier: GPVI Inhibitors Beyond Aspirin